Latest News

Novo Nordisk Reaches Licensing Deal with Lexicon Pharmaceuticals for Novel Obesity Candidate
Novo Nordisk Reaches Licensing Deal with Lexicon Pharmaceuticals for Novel Obesity Candidate

March 28th 2025

Under terms of the deal, Novo Nordisk will obtain global rights to develop, manufacture, and commercialize LX9851 for obesity and metabolic disorders.

Credit: WrightStudio | stock.adobe.com
Oncology Brands Face Uniquely Complex Market Access Challenges: A Specialized Approach for Commercial Success

March 28th 2025

Mitja Alexander Linss, Karger Publishers
The Evolution of Healthcare Communication: Bridging the HCP-Patient Divide

March 28th 2025

FDA Grants Fast Track Designation to Sanofi’s mRNA Chlamydia Vaccine
FDA Grants Fast Track Designation to Sanofi’s mRNA Chlamydia Vaccine

March 28th 2025

Emerging Biopharma Launches: Strategizing in Today’s Global Market

A look at the current landscape and how young companies can set the stage for product launch.

 A look at the current landscape and how young companies can set the stage for product launch.

Conference Coverage

View All
JPM25: Oncology Outlook for 2025
JPM25: Oncology Outlook for 2025

January 20th 2025

Stock.adobe.com
NVIDIA Announces Pharma Partnerships to Expand AI

January 15th 2025

Stock.adobe.com
Moderna Details Product Pipeline and Finances Ahead of JP Morgan Presentation

January 14th 2025

Stock.adobe.com
Biohaven Details Pipeline Update At JP Morgan Conference

January 14th 2025

Latest Videos
Podcasts
Peter Ax, UpScriptHealth
Jennifer Butler

All News